Immune-based therapeutic approaches in COVID-19 - 03/06/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Coronavirus disease 2019 (COVID-19) is a viral disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a member of the Coronaviridae family. On March 11, 2020 the World Health Organization (WHO) has named the newly emerged rapidly-spreading epidemic as a pandemic. Besides the risk-reduction measures such as physical and social distancing and vaccination, a wide range of treatment modalities have been developed; aiming to fight the disease. The immune system is known as a double-edged sword in COVID-19 pathogenesis, with respect to its role in eliminating the pathogen and in inducing complications such as cytokine storm syndrome. Hence, immune-based therapeutic approaches have become an interesting field of COVID-19 research, including corticosteroids, intravenous immunoglobulins (IVIG), interferon therapy, and more COVID-19-specific approaches such as anti-SARS-CoV-2-monoclonal antibodies. Herein, we did a comprehensive review on immune-based therapeutic approaches for COVID-19.
Data availability statement |
Not applicable.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Since the emergence of the virus, COVID-19 has caused morbidities and mortalities worldwide. |
• | The immune system plays a dual role, eliminating pathogens and inducing poorly regulated responses. |
• | Immune-based therapeutic approaches affect both roles and help to resolve disease complications. |
• | These approaches are a promising candidate in controlling poorly regulated responses especially in severely ill patients. |
• | Examples of such modalities include corticosteroids, IVIG, interferons, and monoclonal antibodies. |
Keywords : COVID-19, SARS, Coronavirus, SARS-CoV-2, ARDS, Pandemic, Pneumonia, Immune, Immunotherapy, Corticosteroids, IVIG, Interferon, Monoclonal antibody
Plan
Vol 151
Article 113107- juillet 2022 Retour au numéro
Article précédent
- VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders
- Yibei Wang, Xiaoxue Qin, Yun Han, Bo Li
- Silica nanoparticles: Biomedical applications and toxicity
- Yanmei Huang, Peng Li, Ruikang Zhao, Laien Zhao, Jia Liu, Shengjun Peng, Xiaoxuan Fu, Xiaojie Wang, Rongrui Luo, Rong Wang, Zhuhong Zhang
Bienvenue sur EM-consulte, la référence des professionnels de santé.